Seagen Highlights Immuno-Oncology Data from Broad Portfolio During SITC Virtual Annual Meeting 2020
Seagen Inc. (Nasdaq:SGEN) presented immuno-oncology data at the SITC 35th Annual Meeting, showcasing advancements in antibody-drug conjugates (ADCs) and the proprietary sugar-engineering antibody (SEA) technology. Key findings highlighted the efficacy of MMAE-based ADCs in inducing immunogenic cell death, enhancing the synergy with other immunotherapies. Notable presentations include data for tisotumab vedotin and SEA-TGT, currently in clinical trials. These insights support Seagen's commitment to innovation in cancer treatment and its potential impact on improving patient outcomes.
- Data presented at SITC demonstrates that MMAE-based ADCs enhance immunotherapy efficacy.
- Ongoing trials for SEA-TGT and SEA-CD40 suggest innovative cancer treatment pathways.
- Research supports the use of ADCETRIS in targeting CD30-positive T regulatory cells.
- Actual results may differ from forward-looking statements due to uncertainties in pharmaceutical development.
- Potential adverse regulatory actions could impact product development timelines.
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced the presentation of immuno-oncology data from its broad pipeline of therapies at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting 2020, taking place virtually November 9-14, 2020. Six abstracts will highlight the company’s continued progress in advancing innovative research for marketed and late-stage antibody-drug conjugates (ADCs) and innovative empowered antibody pipeline utilizing its proprietary sugar-engineering antibody (SEA) technology.
Data presented at SITC will demonstrate how Seagen’s monomethyl auristatin E (MMAE)-based ADCs induce immunogenic cell death (ICD) by activating the innate immune cells and changing the tumor microenvironment to a more inflammatory state thereby enhancing the efficacy of other cancer immunotherapies. These findings will be presented for tisotumab vedotin, ladiratuzumab vedotin and across vedotin-based ADCs (Abstracts #617, #618 and #323).
“Our vedotin-based ADC research at SITC illustrates the impact of immunogenic cell death on the tumor microenvironment,” said Roger Dansey, M.D., Chief Medical Officer at Seagen. “Importantly, these data support the mechanistic rationale for combining vedotin-based ADCs with immuno-oncology therapies in the clinic.”
Data will also be presented utilizing Seagen’s proprietary SEA technology, which produces nonfucosylated antibodies that uniquely enhance activity targeting key immune modulating receptors. Preclinical data will be presented from SEA-TGT (Abstract #250), a novel investigational nonfucosylated human IgG1 TIGIT antibody. SEA-TGT is in an ongoing phase 1 clinical trial for patients with solid tumors and lymphoma (NCT04254107). In addition, preclinical data will be presented for SEA-CD40 (Abstract #438), a novel investigational, nonfucosylated human IgG1 antibody targeted to CD40, an immune stimulatory receptor found on antigen-presenting cells. SEA-CD40 is in a phase 1 trial for pancreatic cancer in combination with chemotherapy and a PD-1 inhibitor (NCT02376699).
“We believe our immuno-oncology candidates have a best-in-class potential, creating a strong foundation for our immunotherapy pipeline,” said Scott Peterson, Ph.D., Senior Vice President of Research at Seagen. “Data presented at SITC demonstrate that our sugar-engineered antibodies are differentiated and have the potential to improve efficacy and address unmet needs in cancer.”
Data regarding ADCETRIS® (brentuximab vedotin) will be presented demonstrating its ability to selectively target and kill CD30-positive T regulatory cells (Tregs) that contribute to resistance to cancer immunotherapies (Abstract #696). These data support that ADCETRIS may have an immunomodulatory effect through selective depletion of highly active Tregs.
The abstracts published in advance of the SITC Annual Meeting can be found here. All data presentations will be available on-demand starting on November 11, 2020.
Details of Seagen Presentations at SITC Annual Meeting 2020:
Abstract Title |
Abstract No. |
Presentation Type / Date |
Presenter |
Brentuximab vedotin, a CD30 targeting antibody-drug conjugate, selectively depletes activated Tregs in vitro and in vivo |
#696 |
E-Poster / November 11-14 |
B. Grogan |
Tisotumab vedotin shows immunomodulatory activity through induction of immunogenic cell death |
#617 |
E-Poster / November 11-14 |
E. Gray |
Systemic administration of ladiratuzumab vedotin alone or in combination with pembrolizumab results in significant immune activation in the tumor microenvironment in metastatic breast cancer patients |
#323 |
E-Poster / November 11-14 |
L. Pusztai |
Synergy between SEA-CD40 and chemotherapeutics drives curative anti-tumor activity in pre-clinical models |
#438 |
E-Poster / November 11-14 |
W. Zeng |
SEA-TGT is a nonfucosylated antibody with distinct and amplified effector function activity that leverages the dependencies of anti-TIGIT anti-tumor activity upon FcγR engagement |
#250 |
E-Poster / November 11-14 |
A. Smith |
Vedotin ADCs induce ER stress and elicit hallmarks of ICD across multiple cancer indications |
#618 |
E-Poster / November 11-14 |
K. Klussman |
About Seagen
Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company’s marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.
Forward-Looking Statements
Certain of the statements made in this press release are forward-looking, such as those, among others, relating to the ability of vedotin-based ADCs to enhance the efficacy of immune-oncology therapies, the potential of the Company’s SEA-TGT and SEA-CD40 product candidates and the potential of the Company’s immunotherapy pipeline. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the difficulty and uncertainty of pharmaceutical product development, the risk of adverse events or safety signals, the inability to show sufficient activity in clinical trials and the possibility of adverse regulatory actions. More information about the risks and uncertainties faced by Seagen is contained under the caption “Risk Factors” included in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
